Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001618835-21-000099
Filing Date
2021-05-06
Accepted
2021-05-06 16:02:34
Documents
65
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q evfm-20210331.htm   iXBRL 10-Q 1132872
2 EX-31.1 evfm-3312021xex311.htm EX-31.1 19829
3 EX-31.2 evfm-3312021ex312.htm EX-31.2 19725
4 EX-32.1 evfm-3312021ex321.htm EX-32.1 10902
  Complete submission text file 0001618835-21-000099.txt   6353370

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20210331.xsd EX-101.SCH 47907
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT evfm-20210331_cal.xml EX-101.CAL 80096
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT evfm-20210331_def.xml EX-101.DEF 296451
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20210331_lab.xml EX-101.LAB 613964
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20210331_pre.xml EX-101.PRE 406162
10 EXTRACTED XBRL INSTANCE DOCUMENT evfm-20210331_htm.xml XML 972457
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36754 | Film No.: 21897607
SIC: 2834 Pharmaceutical Preparations